ENPRESSE-21 Drug Patent Profile
✉ Email this page to a colleague
When do Enpresse-21 patents expire, and when can generic versions of Enpresse-21 launch?
Enpresse-21 is a drug marketed by Duramed Pharms Barr and is included in one NDA.
The generic ingredient in ENPRESSE-21 is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ENPRESSE-21?
- What are the global sales for ENPRESSE-21?
- What is Average Wholesale Price for ENPRESSE-21?
Summary for ENPRESSE-21
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Patent Applications: | 277 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ENPRESSE-21 at DailyMed |
US Patents and Regulatory Information for ENPRESSE-21
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Duramed Pharms Barr | ENPRESSE-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 075809-001 | Jul 16, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |